A066830 Stock Overview
Genotech Corporation provides products and services for gene synthesis, genome analysis, and biopharmaceuticals in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Genotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,597.00 |
| 52 Week High | ₩2,695.00 |
| 52 Week Low | ₩1,402.00 |
| Beta | 0 |
| 1 Month Change | 0.44% |
| 3 Month Change | -15.86% |
| 1 Year Change | -38.58% |
| 3 Year Change | -53.10% |
| 5 Year Change | 6.47% |
| Change since IPO | -74.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| A066830 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.1% | -0.6% | -2.4% |
| 1Y | -38.6% | 2.4% | 1.9% |
Return vs Industry: A066830 underperformed the KR Biotechs industry which returned -3.5% over the past year.
Return vs Market: A066830 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A066830 volatility | |
|---|---|
| A066830 Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A066830's share price has been volatile over the past 3 months.
Volatility Over Time: A066830's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | n/a | www.genotech.co.kr |
Genotech Corporation provides products and services for gene synthesis, genome analysis, and biopharmaceuticals in South Korea and internationally. The company offers standard, modified, dual labeled, and synthesis oligonucleotides; and gene synthesis services. It also provides sanger DNA sequencing services, which includes standard DNA, 16S/ITS, and insert clone sequencing, as well as primer walking; next generation sequencing; bioinformatics services; genomic services, such as SNP discovery/analysis and sequence finishing; and molecular diagnostic kits.
Genotech Corporation Fundamentals Summary
| A066830 fundamental statistics | |
|---|---|
| Market cap | ₩8.94b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A066830 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A066830 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A066830 perform over the long term?
See historical performance and comparison